ReviewTherapeutic drug monitoring2026
Interpretive Reference Ranges for Plasma Drug Concentrations in Acute Recreational Drug Toxicity: A Short Communication.
Review in Therapeutic drug monitoring, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAcute recreational drug toxicity (ARDT) is a frequent cause of emergency department presentations; however, clinicians lack guidance for interpreting drug concentrations. Existing terminology ("therapeutic," "toxic," and "lethal") does not reflect the variability observed in ARDT, where tolerance, interindividual differences, and polydrug exposure influence clinical features. This study aimed to develop a descriptive, clinician-oriented framework to categorize illicit and prescription drug concentrations into meaningful interpretive bands.
methodsA literature search identified studies reporting antemortem plasma concentrations in adults. Twenty-four analytes (parent drugs and metabolites) commonly detected in ARDT were included. Concentrations were standardized to ng/mL. For illicit drugs, skewness, histograms, and robust z-scores (median absolute deviation-based; threshold ±3.5) were used to identify and remove outliers. Interquartile- or tertile-based interpretive bands (low, moderate, and high) were assigned according to data set characteristics. Gamma-hydroxybutyrate concentrations were classified using endogenous cutoff values. Prescription medicines were categorized as within or above the therapeutic range based on established reference ranges.
resultsThousand two hundred sixteen plasma concentrations from 79 studies met the inclusion criteria. Illicit drug ranges included analytes with narrow (ketamine, 53-86 ng/mL) and broad (cocaine, 65-193 ng/mL) concentration-effect variability. The endogenous cutoff for gamma-hydroxybutyrate was 5000 ng/mL. Prescription medicine ranges reflected expected therapeutic patterns.
conclusionsThis study proposes a reproducible, percentile-based framework for interpreting plasma drug concentrations in ARDT. The framework provides clinically intuitive, data-driven reference bands to support clinical interpretation, enhance communication between laboratories and clinicians, and offer a scalable foundation for future guideline development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.